Blue Jet Healthcare Limited has scheduled a virtual investor meet with Goldman Sachs India Securities Ltd. for June 12, 2026. The meeting will be conducted in group mode via virtual channels. The company confirmed that no unpublished price sensitive information shall be disclosed during the conference that is not already available in the public domain.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information is also available on the company's official website.

Investor Meet Schedule

Blue Jet Healthcare reported a financial performance for FY26 characterized by strategic investments and mixed segmental results, with revenue from operations declining 8% to INR947 crores compared to the previous year. The company maintained a healthy profit after tax margin of 26% for the fiscal year, supported by other income of INR69 crores, which included an exchange gain of INR36 crores. Management emphasized that FY26 served as a foundational year for capacity expansion and R&D development, positioning the company for a transition into a commercialization and growth cycle in FY27.

Financial Performance

The company's revenue streams showed divergent trends during the year. The contrast media segment demonstrated strong momentum, with full-year revenue increasing 23% to INR495 crores. In Q4FY26, this segment reported revenue of INR193 crores, marking a 91% year-over-year increase. Conversely, the PI/API category faced significant challenges due to customer destocking, particularly for a cardiovascular drug intermediate, leading to a 35% decline in full-year revenue to INR298 crores. The artificial sweetener segment recorded a 2% drop in annual revenue to INR131 crores, though Q4 revenue rose 43% quarter-on-quarter to INR37 crores.

Strategic Expansion and Capex

Blue Jet Healthcare is executing a major capital expenditure plan to bolster its manufacturing capabilities. The company has commenced a greenfield expansion project in Vizag, spread across approximately 100 acres, with a total estimated investment of INR1,000 crores over three years. Phase 1 will focus on manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates. Additionally, the company is progressing with a backward integration project at its Mahad Unit 3 to strengthen supply chain reliability for contrast media. The total capital work in progress (CWIP) as of March 31, 2026, stood at INR301 crores.

Operational Outlook

Management indicated that the destocking impact in the PI segment has normalized, and the company is seeing improved order visibility as it enters FY27. The contrast media segment is expected to maintain positive momentum, driven by new product launches and existing customer partnerships. The company is also strengthening its R&D capabilities with a new center in Hyderabad, involving an investment of INR40 crores, focusing on newer chemistry platforms such as peptide-related intermediates and GLP-1 opportunities. Blue Jet Healthcare ended FY26 as a debt-free company with liquid financial assets of INR400 crores.